Investigational drug · Phase 3
LBL-007
Also called: Alcestobart
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
1 still active
All registered trials
10
Any phase or sponsor naming "LBL-007"
First trial start
2018
Nov 13, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LBL-007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- Non Small Cell Lung Cancer
- Non-small Cell Lung Cancer
- Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
- HNSCC for Phase 2 Dose Expansion
- NSCLC for Phase 2 Dose Expansion
- Malignant Tumors
- Advanced Malignancies
- Head and Neck Squamous Cell Carcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LBL-007" as an intervention, largest first.
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT05635708 · 418 participants · Start Feb 10, 2023 · Primary completion Dec 19, 2025
Drug: Tislelizumab; BGB-A445 and 7 more · For: Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer
Sites: Los Angeles, California; Boston, Massachusetts; New York, New York · 61 sites in all
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesPivotal-lookingCompleted
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04164199 · 404 participants · Start Dec 19, 2019 · Primary completion May 23, 2026
Drug: Tislelizumab; Pamiparib and 11 more · For: Advanced Malignancies
Sites: Miami, Florida; New York, New York; Nashville, Tennessee · 106 sites in all
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell CarcinomaPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT05909904 · 160 participants · Start Aug 2, 2023 · Primary completion Jun 17, 2025
Drug: Tislelizumab; BGB-A425 and 1 more · For: Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer
Sites: Los Angeles, California; Stanford, California; Lone Tree, Colorado · 73 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03744468 · 147 participants · Start Nov 13, 2018 · Primary completion Feb 6, 2025
Drug: Surzebiclimab; Tislelizumab and 1 more · For: Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in; HNSCC for Phase 2 Dose Expansion; NSCLC for Phase 2 Dose Expansion
Sites: Orange, California; Aurora, Colorado; Chicago, Illinois · 40 sites in all
- Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung CancerPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT05577702 · 121 participants · Start Mar 8, 2023 · Primary completion Dec 13, 2024
Drug: Tislelizumab; Ociperlimab and 5 more · For: Non Small Cell Lung Cancer
Sites: Wuhu, China; Beijing, China; Fuzhou, China · 14 sites in all
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT06010303 · 118 participants · Start Nov 8, 2023 · Primary completion May 30, 2025
Drug: LBL-007; Tislelizumab and 1 more · For: Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
Sites: Hefei, China; Beijing, China; Fuzhou, China · 38 sites in all
- A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal CancerPivotal-lookingActive, not recruiting
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT05609370 · 113 participants · Start Jan 29, 2023 · Primary completion May 23, 2025
Drug: Alcestobart; Tislelizumab and 2 more · For: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Sites: Anchorage, Alaska; Gilbert, Arizona; Cerritos, California · 64 sites in all
Nanjing Leads Biolabs Co.,LtdIndustry
NCT05516914 · 98 participants · Start Sep 1, 2022 · Primary completion Jan 30, 2026
Drug: LBL-007 Injection; Tislelizumab Injection and 3 more · For: Malignant Tumors
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 15 sites in all
Nanjing Leads Biolabs Co.,LtdIndustry
NCT05102006 · 80 participants · Start Nov 30, 2021 · Primary completion May 22, 2024
Drug: LBL-007 Injection; Toripalimab Injection · For: Advanced Malignant Tumors
Sites: Bengbu, China; Chongqing, China; Fuzhou, China · 14 sites in all
Nanjing Leads Biolabs Co.,LtdIndustry
NCT04640545 · 79 participants · Start May 12, 2020 · Primary completion Aug 19, 2024
Drug: LBL-007; Toripalimab and 1 more · For: Advanced Melanoma
Sites: Beijing, China; Fuzhou, China; Wuhan, China · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anti-LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial.
Sun D, Chen G, Chen Y, et al. · Clin Cancer Res 2026
- Novel anti-LAG-3 antibody LBL-007 with anti-PD-1 blockade enhances antitumor immunity by promoting T cell-induced apoptosis.
Qin K, Zhou H, Yu X, et al. · Sci Rep 2025
- [A novel fully human LAG-3 monoclonal antibody LBL-007 combined with PD-1 antibody inhibits proliferation, migration and invasion of tumor cells via blocking NF-κB pathway].
Zhou H, Liu J, Wu C, et al. · Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2025
- Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial.
Chen G, Sun DC, Ba Y, et al. · J Hematol Oncol 2025
- Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy.
Yu X, Huang X, Chen X, et al. · MAbs 2019
Also in development for Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- FluoropyrimidinePhase 33 trials
Seattle Project Corporation · Colorectal Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma, Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.